Alcon Labeled Its Eye Drops “Preservative Free.” They Contained a Preservative

The Human Cost: What “Preservative Free” Means to a Real Person

People who seek out preservative-free eye drops are not being precious. Many of them have been prescribed or advised to avoid preservatives because repeated exposure to preservative-containing eye drops is associated with irritation of the ocular surface. Others are simply trying to read a label and make an informed choice about what goes into their eyes, one of the most sensitive parts of the human body, multiple times a day.

Sarah Som-Dotson did what she was supposed to do. She checked the packaging before she bought. She saw “preservative free” printed on the label. She made her decision based on that information and spent her money accordingly. She had no way of knowing that Alcon’s definition of “preservative free” had a silent asterisk: the product contained boric acid, a compound whose entire documented function in multi-dose eye drops is to stop bacteria from growing.

The betrayal here is precise. It is not an ambiguous ingredient list buried in small print. It is an affirmative claim, front-of-label, in plain English, that tells the buyer they are getting something they are not getting. The complaint documents that Plaintiff “has been deprived of her legally-protected interest to obtain true and accurate information about the consumer products she buys.” That is a clinical way of saying: she was lied to, she paid for the lie, and she had no way to catch it.

The complaint also documents that Plaintiff suffered “stress, aggravation, frustration, loss of trust, loss of serenity, and loss of confidence in product labeling.” That last one matters beyond this single case. When a company with the reach and resources of Alcon puts false information on a label and sells it at scale, the damage is not just to the individual buyer. It erodes the basic social contract that makes consumer choice meaningful. If “preservative free” can mean “contains a preservative,” then no label can be trusted, and the entire premise of informed purchasing collapses.

The class potentially numbers in the thousands or millions. Each one of them bought a product believing a specific thing about what was in it. Each one of them was wrong, because Alcon said so on the box.

Legal Receipts: What the Complaint Says in Its Own Words

These are direct quotes from the complaint filed in Case 2:26-cv-04898. Nothing is paraphrased.

“During the Class Period all of Defendant’s Systane products (the ‘Products’) were advertised as containing ‘preservative free’ when they contained boric acid.”

• This establishes the core factual claim: the “preservative free” label was applied across the Systane product line during the class period, not on a single product variant, and the products contained boric acid throughout that same period.
• The complaint states this as a fact to be proven, not merely alleged, which means Plaintiff’s counsel has assessed the evidence as sufficient to make this affirmative assertion to a federal court.

“Boric acid inhibits the growth of bacteria by disrupting essential metabolic processes of microorganisms including protein synthesis and enzymatic function.”

• This is the mechanism statement. It establishes that boric acid is not merely incidentally present; it functions as a preservative by the standard scientific definition: it prevents microbial growth.
• The complaint supports this with a citation to a peer-reviewed journal: Savić, S. D., Ćirić, A., & Pantelić, I. (2020), Journal of Pharmaceutical Sciences, 109(12), 3574–3581.

“Boric acid is used as a preservative in cosmetics, including multidose eyedrops.”

• This ties boric acid’s established industry use directly to the product category at issue: multi-dose eye drops. Alcon’s product is a multi-dose eye drop. The connection is direct.
• This also means the claim is not novel or invented for litigation. The use of boric acid as a preservative in eye drops is documented in pharmaceutical science literature that Alcon, as a manufacturer in this space, would have access to and responsibility for knowing.

“Defendant knew that their representations and omissions were untrue and misleading, and deliberately made the aforementioned representations and omissions in order to deceive reasonable consumers like Plaintiff and other Class and Sub-Class Members.”

• This is the knowledge and intent allegation. The complaint does not frame this as negligence or oversight; it alleges deliberate deception by a company that knew its label was false.
• The complaint further supports this by noting: “Defendant, and not Plaintiff, the Class, or Sub-Class, knew or should have known that the boric acid contained in the Products was a preservative, and that Plaintiff, the Class, and Sub-Class members would not be able to tell the Products contained preservatives unless Defendant expressly told them.”

“Defendant coerced consumers to base their purchasing decision in material part on false claims, thereby fraudulently, deceptively, and unfairly increasing consumer demand for the product. Defendant profited from these acts by extracting additional funds from consumers than otherwise would not have been paid for Class Products, and also harmed competitors by luring would-be consumers of competitive products away from law-abiding products that were not so falsely advertised.”

• This paragraph does something important: it names two separate victims of the alleged scheme. First, consumers who paid a premium or made a choice based on a false claim. Second, competitors who were truthfully labeling their products and lost sales to Alcon’s false advertising.
• The use of “coerced” is legally significant under California’s UCL framework, which requires showing that the injury was one consumers could not reasonably have avoided. The complaint argues that because the false claim was on the label, and consumers had no independent means to detect boric acid’s preservative function, the deception was structurally unavoidable.

Public Deception: What Alcon Said vs. What Was in the Bottle

The complaint documents a precise gap between the claim Alcon placed on its label and the documented chemical reality of the product.

• Alcon’s claim: The Systane products were labeled “preservative free,” a claim Plaintiff reviewed before purchasing and that directly drove her decision to buy. The documented reality: The products contained boric acid, a compound classified as a preservative in pharmaceutical science literature and used specifically as a preservative in multi-dose eye drops.
• Alcon’s implicit promise: That the “preservative free” label reflected the actual formula of the product. The documented reality: The complaint alleges Alcon knew boric acid was a preservative and knew consumers lacked the scientific background to detect this on their own. The omission was therefore structural, built into the product and the information asymmetry between manufacturer and buyer.
• The complaint specifically alleges that Alcon’s false label “increased consumer demand for the Products by incentivizing consumers to purchase them to receive desirable product features” and allowed Alcon to “sell the Products at a greater price and/or in greater quantity than if Defendant did not include the challenged labeling.”

Profit-Maximization at All Costs: The Label Was a Sales Tool

The complaint makes a direct economic argument: the “preservative free” label was not an oversight, it was a revenue mechanism. Every element of this allegation points to a deliberate business decision, not a formulation error.

• The complaint alleges that “producers of consumer products, like Defendant, use consumer product labeling to increase consumer demand for products based on the perceived features or benefits of the products thereby increasing the price producers can charge for their products and/or the quantity they can sell.” This is the baseline economic logic Alcon understood and exploited.
• Specifically, the complaint states Alcon “increased consumer demand for the Products by incentivizing consumers to purchase them to receive desirable product features” through the “preservative free” label, while knowingly failing to deliver that feature.
• The result, per the complaint, was that Alcon “has been able to sell the Products at a greater price and/or in greater quantity than if Defendant did not include the challenged labeling, but without providing consumers with the promised product feature.”
• The complaint characterizes this as “extracting additional funds from consumers than otherwise would not have been paid for Class Products.” The label premium was built on a lie.
• The complaint also identifies a second economic victim: “law-abiding” competitors who were not falsely advertising and lost market share to Alcon’s deceptive label. Alcon allegedly gained competitive advantage by breaking the rules that its competitors followed.

How the Scheme Worked: Anatomy of a False Label

Regulatory Gray Zones: How the Label Got Away With It

The complaint exposes a gap between scientific classification and consumer-facing labeling standards that Alcon appears to have exploited to maintain a “preservative free” claim on a product containing a preservative.

• Boric acid’s function as a preservative is documented in peer-reviewed pharmaceutical science, including its specific use in multi-dose eye drops. However, the complaint implies that no regulatory body had explicitly required Alcon to update its label to reflect this classification before the lawsuit was filed, allowing the company to continue the “preservative free” claim without an immediate enforcement action compelling correction.
• The complaint’s reliance on California’s False Advertising Law (§ 17500) and Unfair Competition Law (§ 17200) to pursue this claim suggests that federal labeling frameworks governing eye drops may not have independently required the correction that California consumer protection law demands. The litigation is the correction mechanism, not prior regulatory enforcement.
• The complaint notes that “Plaintiff could not have known that the Products contained a preservative” because of Defendant’s labeling, and that consumers “would not be able to tell the Products contained preservatives unless Defendant expressly told them.” This information asymmetry is itself a regulatory gap: the law put the disclosure obligation on Alcon, but no enforcement mechanism caught or corrected the false claim before consumers were harmed at scale.

Legal Minimalism: Complying With the Letter, Ignoring the Purpose

The complaint documents a textbook case of a company exploiting the gap between what a label technically says and what consumer protection law requires it to mean.

• California Business & Professions Code § 17500 prohibits advertising that is “untrue or misleading” and that “by the exercise of reasonable care should be known, to be untrue or misleading.” The law was designed to protect consumers from being deceived into purchases they would not otherwise make. Alcon’s “preservative free” label hit every element of what § 17500 was built to prevent: a specific false feature claim, applied to a product, to drive sales.
• The complaint specifically alleges that Alcon knew its label was false. The legal standard under § 17500 does not even require actual knowledge; “by the exercise of reasonable care should be known” is sufficient. Alcon, as a pharmaceutical manufacturer producing multi-dose eye drops, had every reason to know the scientific classification of its own ingredients, making the “should have known” standard trivially easy to meet.
• Under California’s UCL (§ 17200), the “fraudulent” prong does not require proving that any individual consumer was actually deceived. The standard is whether the practice was “likely to deceive members of the public.” A front-label “preservative free” claim on a product containing a substance classified as a preservative in pharmaceutical literature is precisely what that standard was designed to catch.

Societal Impact: Who Gets Hurt When a Label Lies

Public Health

The consequences of misleading labeling on a product applied directly to the eyes of potentially millions of people are concrete, not abstract.

• Consumers who sought “preservative free” eye drops specifically to avoid ocular surface exposure to preservatives were buying a product that, according to the complaint, contained a compound with documented bacteriostatic effects. Whether or not boric acid at the concentration used causes harm is a separate clinical question; the point is that consumers making medically or preference-based decisions to avoid preservatives were denied the information they needed to make that choice.
• The complaint acknowledges that Plaintiff “is interested in purchasing the Products again in the future, and as a result she will be harmed if Defendant is not forced to correct the fraudulent labeling or remove the boric acid.” This establishes an ongoing harm, not a one-time transaction failure: without a court order, every future buyer faces the same deception.
• The class is alleged to number in the “thousands, if not millions.” The scale of people receiving false information about what they are putting in their eyes is not a footnote. Eye drops are a health product. The “preservative free” designation is a health claim. Falsifying a health claim at this scale is a public health issue.

Economic Inequality

The financial harm documented in this complaint follows a pattern that consistently falls hardest on people with the least ability to absorb it.

• The complaint documents that consumers paid a price premium specifically because of the “preservative free” label. That premium was extracted from buyers who trusted the label and had no technical means to verify it independently. The people most likely to be unable to independently verify pharmaceutical ingredient classifications are also the people who can least afford to pay a premium for a feature they do not receive.
• The class action mechanism exists precisely because the individual economic harm per consumer, while real and documented, is small enough that no individual would rationally pursue litigation. This is a feature, not a bug, of the scheme: Alcon collects small amounts from enormous numbers of people, and each individual harmed has insufficient incentive to stop it. The class action is the only tool available at this scale.
• The complaint notes that Alcon also harmed competitors who were truthfully labeling their products. Honest competitors who did not claim “preservative free” falsely lost sales to Alcon’s mislabeled product. This represents economic harm to the market itself: companies that follow the rules are penalized for doing so.

This Is the System Working as Intended

The Alcon Systane case is not a malfunction. The structure of this scheme and the legal tools available to address it together reveal a system that allows corporate deception at scale to persist until private litigants absorb the cost of stopping it.

• Alcon is a Delaware corporation headquartered in Texas, selling products nationally, with the alleged deception occurring across every state where Systane was sold. The enforcement action that caught this was filed by a private plaintiff under California state law, not by a federal regulator. The FDA, which oversees labeling of eye drops as drug or device products, is not named in the complaint. Whatever federal oversight existed, it did not catch or correct this label before the lawsuit was filed.
• The complaint explicitly states that “the misleading and false advertising described herein presents a continuing threat” and that “Defendant persists and continues to engage in these practices.” The label was still false at the time of filing. This means the scheme ran long enough for a class period measured in years, accumulated purchasers potentially numbering in the millions, and was stopped only when a private citizen and her lawyers brought a lawsuit, not when a regulator acted.
• The information asymmetry between Alcon and its customers is a structural feature of the consumer product market, not an accident. Alcon employs scientists who understand what boric acid does. Its customers read labels. The law was supposed to close this gap by requiring truthful labeling. The law failed here, and the gap was exploited for profit.
• The complaint documents that the individual per-unit harm is too small for any single consumer to litigate. This is the rational economics of consumer fraud at scale: charge a little more than you should from a very large number of people, and the math protects you from individual accountability. The class action mechanism is the only structural response available, and it relies entirely on private attorneys taking the risk of pursuing it.

What a Legitimate Fix Looks Like

Editorial analysis. The following recommendations are the authors’ assessment based on the documented failure modes of this case. They are not findings of the source document.

The core structural failure this case exposes: a pharmaceutical company can label an eye drop with a health claim it knows to be false, sell the product to potentially millions of people, and face no corrective action until a private citizen files a class action lawsuit at her own legal risk and expense.

Regulatory Track

• The FDA should clarify and enforce its authority over “preservative free” claims on eye drop labels as substantiated health claims requiring documented ingredient-function verification before use. A manufacturer should be required to demonstrate, on file with the agency, that no ingredient in a “preservative free” product functions as a preservative under established pharmaceutical science definitions before that claim may appear on the label.
• The FTC, which oversees truthful advertising, should issue guidance specifically addressing ingredient function claims on health and personal care products. The current gap between what an ingredient does and what a label claims it does not contain is an enforcement gap the FTC has the authority to close.
• State consumer protection agencies in states beyond California should audit “preservative free” claims on multi-dose eye drops as a category, not only in response to individual complaints. The Alcon case was brought under California law. Buyers in 49 other states face the same label with less direct legal recourse.

Legislative Track

• Congress should strengthen the legal standard for health-adjacent ingredient claims on consumer products by requiring that any “free from” label claim be substantiated by ingredient function testing, not just ingredient presence testing. A product can contain a preservative without listing “preservative” as an ingredient name; the function, not merely the name, should determine what a label may claim.
• State legislatures should consider expanding the statutory damages available under consumer protection laws for false health-adjacent claims on personal care products, to create a deterrent that exceeds the profit from the deception. California’s current UCL framework allows restitution and injunctive relief; whether that is sufficient to deter a corporation operating nationally is an open question that the legislature should examine.

Corporate Governance Track

• Alcon’s labeling compliance process should require cross-functional sign-off between its scientific and regulatory teams before any “free from” claim is approved for a consumer label. The complaint alleges that Alcon knew boric acid was a preservative. If that knowledge existed inside the company and the label was approved anyway, the internal approval process failed and should be restructured to prevent recurrence.
• Alcon should be required, as part of any settlement, to conduct a full audit of all “free from” and negative ingredient claims across its product line and correct any claim that is inconsistent with the documented function of the product’s ingredients. One false label on one product line suggests a systemic labeling review process that does not adequately cross-reference ingredient function.
• The complaint seeks corrective advertising as a remedy. Any corrective advertising order should require Alcon to affirmatively notify identifiable purchasers of the Systane products, including through Amazon purchase records, that the “preservative free” label was inaccurate and that boric acid is present in the formula.